Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3751 AL 3765

High level of Mn in brain is a risk for Alzheimer disease

Yu Q, Zhou YZ.

Sheng Li Xue Bao. 2018 Apr 25;70(2):193-200.

Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F.

JAMA Neurol. 2018 Sep 1;75(9):1114-1123. doi: 10.1001/jamaneurol.2018.0894.

Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review

Ruthirakuhan M, Lanctôt KL, Di Scipio M, Ahmed M, Herrmann N.

Alzheimers Dement. 2018 Oct;14(10):1344-1376. doi: 10.1016/j.jalz.2018.04.013. Epub 2018 Jun 23.

Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease

Tao Y, Peters ME, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Munro CA.

Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457. doi: 10.1177/1533317518783278. Epub 2018 Jul 3.

Sex differences in Alzheimer disease - the gateway to precision medicine

Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, Baracchi F, Girouard H, Misoch S, Giacobini E, Depypere H, Hampel H; Women’s Brain Project and the Alzheimer Precision Medicine Initiative.

Nat Rev Neurol. 2018 Aug;14(8):457-469. doi: 10.1038/s41582-018-0032-9.

Low expression of aging-related NRXN3 is associated with Alzheimer disease: A systematic review and meta-analysis

Zheng JJ, Li WX, Liu JQ, Guo YC, Wang Q, Li GH, Dai SX, Huang JF.

Medicine (Baltimore). 2018 Jul;97(28):e11343. doi: 10.1097/MD.0000000000011343.

18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy

Smailagic N, Lafortune L, Kelly S, Hyde C, Brayne C.

J Alzheimers Dis. 2018;64(4):1175-1194. doi: 10.3233/JAD-171125.

DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease

Xu LZ, Li BQ, Jia JP.

Mol Neurobiol. 2019 Apr;56(4):2838-2844. doi: 10.1007/s12035-018-1242-2. Epub 2018 Jul 31.

The emerging risk of exposure to air pollution on cognitive decline and Alzheimer's disease - Evidence from epidemiological and animal studies

Kilian J, Kitazawa M.

Biomed J. 2018 Jun;41(3):141-162. doi: 10.1016/j.bj.2018.06.001. Epub 2018 Jul 17.

Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study

Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, Andrieu S, Gardette V; MAPT/DSA study group.

Br J Clin Pharmacol. 2019 Jan;85(1):71-99. doi: 10.1111/bcp.13734. Epub 2018 Oct 17.

Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis

Lucchetta RC, da Mata BPM, Mastroianni PC.

Pharmacotherapy. 2018 Oct;38(10):1010-1020. doi: 10.1002/phar.2170. Epub 2018 Sep 6.

Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?

Merlo S, Spampinato SF, Sortino MA.

CNS Neurosci Ther. 2019 Jan;25(1):5-13. doi: 10.1111/cns.13050. Epub 2018 Aug 12.

Definition of Late Onset Alzheimer's Disease and Anticipation Effect of Genome-Wide Significant Risk Variants: Pilot Study of the APOE e4 Allele

De Luca V, Spalletta G, Souza RP, Graff A, Bastos-Rodrigues L, Camargos Bicalho MA.

Neuropsychobiology. 2019;77(1):8-12. doi: 10.1159/000490739. Epub 2018 Aug 15.

Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors

Takeda S.

Neurosci Res. 2019 Apr;141:36-42. doi: 10.1016/j.neures.2018.08.005. Epub 2018 Aug 16.

Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the (18)F-AV-1451 Tracer for Tau Imaging

He M, Baker SL, Shah VD, Lockhart SN, Jagust WJ.

IEEE Trans Med Imaging. 2019 Mar;38(3):697-709. doi: 10.1109/TMI.2018.2870441. Epub 2018 Sep 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias